Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
A new approach to HIV prevention currently being studied includes the use of microbicides,
substances that kill microbes. Tenofovir disoproxil fumarate (TDF) and
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) are oral, FDA-approved, anti-HIV drugs,
and tenofovir gel is an experimental microbicide. The purpose of this study is to determine
the safety and effectiveness of daily tenofovir 1% gel compared to a vaginal placebo gel, and
the safety and effectiveness of oral TDF and oral FTC/TDF compared to an oral placebo in
preventing HIV infection among women at risk for sexually transmitted infections.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Microbicide Trials Network
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir